913623-66-2Relevant academic research and scientific papers
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
-
Page/Page column 42, (2010/11/26)
The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atheroscler
Discovery of ((4R,5S)-5-amino-4-(2,4,5-trifluorophenyl)cyclohex-1-enyl)-3- (trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor
Pei, Zhonghua,Li, Xiaofeng,Von Geldern, Thomas W.,Madar, David J.,Longenecker, Kenton,Yong, Hong,Lubben, Thomas H.,Stewart, Kent D.,Zinker, Bradley A.,Backes, Bradley J.,Judd, Andrew S.,Mulhern, Mathew,Ballaron, Stephen J.,Stashko, Michael A.,Mika, Amanda K.,Beno, David W. A.,Reinhart, Glenn A.,Fryer, Ryan M.,Preusser, Lee C.,Kempf-Grote, Anita J.,Sham, Hing L.,Trevillyan, James M.
, p. 6439 - 6442 (2008/01/27)
Dipeptidyl peptidase IV (DPP4) deactivates glucose-regulating hormones such as GLP-1 and GIP, thus, DPP4 inhibition has become a useful therapy for type 2 diabetes. Optimization of the high-throughput screening lead 6 led to the discovery of 25 (ABT-341),
